Activated platelets play a role in the pathogenesis of coronary heart disease (CHD). Following activation, platelets change shape, aggregate, and release several bioactive substances. The aim of this review is to identify if there is a simple and cost-effective method that indicates platelet activation and predicts the risk of CHD and vascular events. The rationale for identifying high-risk patients is to reduce their risk of vascular events by administering appropriate and effective antiplatelet treatment, like aspirin, clopidogrel, or combination regimens. Many laboratory tests estimating platelet activity have been described. Some are relatively simple, such as spontaneous or agonist-induced platelet aggregation. Other tests include measuring the mean platelet volume (MPV) or plasma soluble P-selectin levels. Some more complex tests include flow cytometry to determine platelet GP Ilb/Illa receptors, platelet surface P-selectin, plateletmonocyte aggregates, and microparticles. Only few prospective studies assessed the predictive value of platelet activation in healthy in-Platelets play an important role in thrombus formation and the pathogenesis of atherosclerosis (1). Platelet activation can be influenced by genes as well as several diseases and vascular risk factors (and their treatment) (2-10). For example, enhanced platelet activation has been reported in hypertensive patients (11) (12) (13) (14) (15) . In turn, antihypertensive drugs (e.g., nitroprusside, nebivolol, doxazosin, and angiotensin II receptor antagonists) inhibit platelet aggregation by increasing nitric oxide (NO) bioactivity or decreasing serotonin-or angiotensin II-induced platelet
dividuals. Although the MPV seems an 'easy method, there are insufficient data supporting its ability to predict the risk of a vascular event in healthy adults. Platelet aggregation, in whole blood or in platelet-rich plasma was not consistently predictive of vascular risk. Soluble P-selectin measurement is a promising method but it needs further evaluation. Flow cytometry methods are costly, time-consuming, and need specialized equipment. Thus, they are unlikely to be useful in estimating the risk in large numbers of patients. There is as yet no ideal test for the detection of platelet activation. Each currently available test has merits and disadvantages. Simple methods such as the MPV and the determination of platelet release products need further evaluation. Key Words: Platelet activation-Platelet aggregation-Platelet adhesion-Coronary heart disease-Antiplatelet treatment-Mean platelet volume (MPV)-Spontaneous platelet aggregation (SPA). activation (11) (12) (13) (14) (15) . Platelets may also be involved in the pathogenesis of the atherothrombotic complications associated with diabetes mellitus (16, 17) . Furthermore, insulin resistance, obesity, and leptin levels may influence platelet and endothelial cell function in experimental models and patients (18) (19) (20) (21) (22) .
Dietary habits, such as alcohol and fish consumption and other lifestyle-related factors (e.g., physical exercise and smoking), can also influence platelet function (23) (24) (25) (26) (27) . There is evidence that pre-existing cerebrovascular, coronary artery, or peripheral arterial disease are associated with platelet activation and increased thrombotic risk (28) (29) (30) (31) (32) (33) (34) (35) (36) (37) (38) .
Emerging risk factors such as fibrinogen, C-reactive protein (CRP), homocysteinemia, and lipoprotein (a) may also contribute to platelet activation and thus increase the risk of CHD (39) (40) (41) (42) (43) (44) (45) . Antiplatelet therapy significantly reduces the risk of thrombotic events in these patients (29) (30) (31) (32) (33) (34) (35) (36) (37) . Lipid-lowering drugs (e.g., statins) can also exert an anti-thrombotic effect and may act synergistically with antiplatelet agents (46) (47) (48) (49) .
Therefore, platelet activity can be influenced by a multitude of variables. It follows that it is difficult to predict the extent of platelet hyperactivity in an individual. It is also unclear if drugs, other than platelet inhibitors, exert some of their beneficial action by influencing platelet function.
Because platelets play a central role in the pathogenesis of thrombosis, a considerable amount of research has been carried out to investigate the mechanism involved in platelet activation . This includes genetic studies (6) (7) (8) (9) (10) . In spite of this extensive research, a practical and reliable index of platelet activation has not been found. A test that predicts in vivo platelet activation would allow the detection of high-risk patients and ensure the subsequent administration of effective treatment. Therapeutic options in the presence of persistent platelet activation may include using an alternative drug, or adding another platelet inhibitor with a different mode of action (29) (30) (31) (32) (33) (34) (35) (36) (37) (50) (51) (52) (53) (54) (55) .
The aim of this review is to consider the studies that assessed the value of platelet activation markers and to suggest any "best choice." PLATELETS AS PREDICTORS OF VASCULAR EVENTS Several studies have shown that increased platelet activity is associated with a greater risk of vascular events (51-55, 64-68,70-75) . Platelet activity seems to have a circadian variation. A bimodal platelet aggregation response after addition of agonists, one in the morning and the other in the afternoon, has been reported (76, 77) . However platelet adhesion only shows a peak in the morning. The incidence of acute coronary events and sudden cardiac death also follows a circadian pattern with an increased incidence of cardiovascular events during the early morning hours (76, 77) . Although this correlation does not establish a causal effect, it provides additional evidence linking platelet hyperactivity with vascular events (76, 77) .
Several epidemiologic studies assessed the value of platelet activity as a predictor of vascular events. The Caerphilly Collaborative Heart Study recruited a general population of 2,398 men aged between 49 and 66 years in 1979 to 1982 (78) (79) (80) (81) (82) . The risk of CHD and the association with platelet aggregation measurements was assessed. Platelet activation in response to several agonists was estimated by two different methods, optical densitometry and impedance changes in platelet rich plasma (PRP) and whole blood, respectively. There was insufficient evidence to show that these methods can predict the risk of CHD. However, there was a trend in predicting events occurring early after testing. Surprisingly, patients with the least platelet response in PRP and whole blood showed the highest stroke incidence (78) (79) (80) (81) (82) .
Another prospective study recruited 487 healthy middle-aged men (83) . Platelet counts and activation were assessed in a random subsample of 150 men. The follow-up period was 13.5 years. Those with higher platelet counts and a rapid aggregation response after the addition of adenosine diphosphate (ADP) had a significantly higher cardiovascular mortality (83) .
A prospective trial evaluated the role of soluble P-selectin in apparently healthy women, as a potential marker of the risk for CHD (73) . This study recruited 115 women in whom CHD subsequently developed, among the 28,263 participants of the Women's Health Study (73) . The control group included 230 age-and smokingmatched women who remained free of disease for 3.5 years. Mean levels of soluble P-selectin were significantly (p = 0.003) higher among those in whom CHD subsequently developed. This effect was independent of other coexisting risk factors. The greatest risk was observed among women with the highest circulating levels of P-selectin (73) .
Some surveys including patients with vascular disease also predicted the risk of CHD by using simple methods. Spontaneous platelet aggregation (SPA) was assessed in 149 patients with previous myocardial infarction (MI) (84) . The follow-up period was 5 years. SPA was assessed at entry and at 6-month intervals and graded as positive, intermediate, and negative according to the recorded time for SPA. Patients using aspirin or other antiplatelet drugs were excluded. This study concluded that positive (within 10 minutes) SPA represented a higher risk of a subsequent cardiac event or death during the following 5 years, thus suggesting a positive link between platelet activity and CHD (84) .
In another study, the mean platelet volume (MPV) was used as an indicator of platelet activity in 1,716 men 6 months after their first MI (85) . The MPV was strongly correlated with the incidence of death and recurrent MI within a 2year follow-up period (85) .
Another study recruited 373 patients with previous MI or stable angina (53) . Patients with increased MPV > 11.6 fl had a higher risk of developing MI as compared to those with MPV values between 7.9 and 9.8 fl (53) .
Platelet size and count were determined in 981 patients with angina (86) . After coronary angiography, 97 patients had non-cardiac chest pain and constituted the control group while the remaining 884 had single-, double-, or triple-vessel disease. Patients with cardiac disease had an increased platelet size compared with controls (p<0.01). Patients with unstable angina had a decreased platelet count compared to patients with stable angina (p<0.05) or controls (p<0.05). Furthermore, patients requiring immediate angioplasty had a decreased platelet count and an even greater platelet size when compared with the rest of the population with unstable angina. This pattern suggests that unstable angina is associated with platelet destruction. The larger, more reactive platelets might be the cause of an ongoing coronary artery obstructive process (86) .
Platelet count alterations also occur during the course of acute MI. On admission, patients with MI had significantly lower platelet counts in comparison with healthy controls and patients with other vascular diseases (87, 88) . These changes probably occurred in parallel with alterations in platelet size and function, and correlate with infarct size as indicated by the level of lactic dehydrogenase (LDH) activity (87, 88) . This phenomenon may reflect the increased consumption of platelets.
Aggregometry and thromboxane A2 (TXA2) release were determined in 71 consecutive patients with acute chest pain (89) . Platelets obtained from the patients with an acute MI were significantly more aggregable and released more TXA2.
Platelets from 18 patients with coexisting vascular disease, even in the absence of MI, had increased aggregability and TXA2 release but to a lesser extent than those with a MI (89). In contrast, 18 patients with no vascular disease or MI had similar aggegability and TXA2 release with the healthy controls (89) .
Another study investigated whether elevated levels of monocyte-platelet aggregates (a sensitive marker of platelet activation) predict the risk of MI among patients (n=211) with acute chest pain (55) . Circulating monocyte-platelet aggre-gates were detected by flow cytometry. Acute MI was diagnosed in 61 patients. These patients had significantly higher monocyte-platelet aggregate counts than those without MI. Additionally, 35 of the 61 patients with MI had a normal creatine kinase (CK) isoenzyme ratio at presentation while monocyte-platelet aggregate levels were elevated. This indicates that platelet activation occurs early during the MI process (55, (90) (91) (92) .
Platelet reactivity may also play a role in the pathogenesis of complications after percutaneous angioplasty (PTCA) and stent implantation. Platelet aggregation was determined by flow cytometry analysis of surface P-selectin and activation of GP IIb/Illa platelet surface glycoproteins in whole blood from 120 patients before PTCA (93) . Patients with greater platelet reactivity had a higher incidence of early restenosis and MI.
These patients also had a higher incidence of MIs and repeated revascularizations during the next 30 to 90 days. Therefore, patients with hyperactive platelets may benefit more from intensive antiplatelet therapy at the time of stenting (93) (94) (95) (96) .
Genetic features may also influence platelet hyperactivity. The LL genotype of the SLC6A4 polymorphism (related with platelet serotonin metabolism) was associated with the risk of MI in the ECTIM study (7) . The LL genotype was found in 35.5% of the 671 patients with MI and in 28.1% of the 688 controls. Thus, the odds ratio for MI associated with this genotype was 1.40 (p = 0.0047). The investigators proposed that this higher risk of MI was attributed to serotonin-mediated platelet activation (7) . Therefore, the evidence shows that activated platelets predict the risk of CHD in healthy individuals and patients with a previous MI or angina. Furthermore, platelet inhibitors significantly reduced the risk of vascular events in several prevention trials (31-37,94-99); some of these trials included patients undergoing stenting (94) . However, the vast majority of these intervention trials did not include a test of platelet function (31) (32) (33) (34) (35) (36) (37) (94) (95) (96) (97) (98) (99) .
THE SEARCH FOR AN IDEAL METHOD
OF ASSESSING PLATELET HYPEREACTIVITY TO PREDICT VASCULAR RISK Several laboratory techniques have been developed to detect platelet activation. These include measurements of platelet number and size, the tendency to form aggregates, and the con-centration of released substances after platelets have been activated. These tests have different limitations and advantages.
Mean Platelet Volume
Several studies proposed that a larger MPV is an indicator of increased in vivo platelet activation (14, (51) (52) (53) (61) (62) (63) 85, (100) (101) (102) (103) (104) (105) (106) (107) (108) (109) (110) (111) (112) . The MPV correlates with platelet activity whether measured as aggregation, thromboxane A2 (TXA2) or 3-thromboglobulin (P-TG) release, or adhesion molecule expression (61) . Furthermore, the MPV is increased in several vascular diseases (MI, cerebral infarction) and when risk factors for vascular diseases are present (53, 85 ). An elevated MPV can also predict the outcome in vascular thrombotic events such as myocardial and cerebral infarction (102, 103) .
Modern counters in routine use provide platelet volume histograms in whole blood. The distribution of MPV, in PRP obtained from normal volunteers, ranges between 7.10 and 8.02 fl for women and 7.01 and 7.92 for men while the mean MPV value in PRP is 7.43 fl (51,52). However, large variations in MPV are seen even in healthy subjects. Age, gender, and the number of circulating platelets influence this distribution. Anticoagulants used for the collection of blood, storage temperature, and the time between collection and testing may also interfere with the MPV measurement (51, 52) . When MPV determination occurs in citrate, MPV decreases during the first 2 hours. When EDTA is used as an anticoagulant, the opposite effect was found. The MPV increases steadily over time (51, 52) . Some investigators propose that routine MPV measurements can be performed with better accuracy and reproducibility by using high concentrations (1:4 v/v with blood) of sodium citrate as anticoagulant, in contrast with similar measurements made at low (1:9 v/v with blood) sodium citrate concentrations (104) . Furthermore, these measurements are not influenced by the time elapsed since blood collection, unlike when EDTA is used (104) (105) (106) .
Some other factors influence MPV determination. Fasting individuals with elevated triglyceride (TG) levels have an inverse relation between MPV and TG levels (51) . Because elevated TG levels are a predisposing factor for CHD, one could assume that the MPV should be increased. However, paradoxically, the MPV is inversely related with TG levels (51) .
MPV is also altered by the addition of agonists. For example, platelet stimulation by collagen can increase the MPV (51) . Several other substances can also influence the MPV. Serotonin and ADP induce platelet shape change and increase the MPV (14) . The increase in MPV induced by serotonin is inhibited by doxazosin, an x1-adrenoceptor antagonist used for the treatment of mild hypertension and benign prostatic hyperplasia (14) . This finding together with those of another study suggest that doxazosin can also block some serotonin-mediated actions (107) . Similarly, losartan, an angiotensin II antagonist, decreases the MPV elevation induced by angiotensin II (108) .
A powerful endogenous vasoconstrictor, endothelin-1 (ET-1), activates platelets and it can increase the MPV when added with other agonists (109) . This deleterious effect of ET-1 on platelet activation was inhibited by naftidrofuryl (109) . Dexfenfluramine, a drug that was used in the past to treat obesity, can induce platelet activation (serotoninergic mechanism) and a subsequent increase in MPV (110) .
MPV measurements could also be influenced by the method used. Some high-resolution counters can detect minimal alterations in platelet size. The resolution of these counters is ± 0.07 fi, whereas counters in routine hematology laboratories usually have a resolution 0.28 fl (62, 111) . Thus, high-resolution counters may prove to be useful in detecting platelet activation before and after treatment with antiplatelet drugs. However, the MPV determination with these high-resolution counters needs to be performed in PRP (62, 111) .
Another controversy about the method for MPV measurement is whether whole blood or PRP is preferable. Whole blood methods are suitable for assessing vascular risk in large groups of patients, while determination in PRP is preferable for research purposes because of the higher resolution (51) (52) (53) (61) (62) (63) . Although the PRP method has increased sensitivity, an additional disadvantage is centrifugation because this could cause platelet activation in vitro (51) (52) (53) (61) (62) (63) . Thus, hyperactive platelets could be lost during this step. Released ADP or serotonin could also artefactually increase the MPV during centrifugation (112) .
In addition to the selection of anticoagulants, there is a great need to standardize storage time and temperature. For example, in ten healthy volunteers, the MPV determination, in whole blood using EDTA as anticoagulant, was not significantly altered if the test was performed within 10 minutes, 30 minutes, or 2 hours after venupuncture. A maximum MPV increase of 0.5 fl was observed when the test was performed within 2 hours after sampling (53) . Regarding temperature, exposure to 4°C increases the MPV, whereas incubation at 37C lowers the MPV (51) . Therefore, further studies need to define the ideal temperature for MPV determination (51, 105) .
When MPV determination is better standardized, the wide use of this test may allow the detection of high-risk patients with hyperactive platelets and the monitoring of the efficacy of the antiplatelet treatment. Surprisingly, the efficacy of antiplatelet treatment, represented by a reversal in the MPV, does not seem to have been documented (53) . In contrast, in antihypertensive or lipid-lowering treatment we monitor the effect of drugs to ensure that target values have been achieved. Successful monitoring of antiplatelet treatment by a simple low-cost and rapid test would allow us to alter the initial choice of antiplatelet treatment. For example, combination regimens (e.g., aspirin plus clopidogrel) may be more effective than monotherapy (30-37,94-98).
Radiolabeling Methods
Radiolabeling methods have been used mainly to assess platelet kinetics and life span. Radionuclides commonly used for this purpose were chromium-51 (51Cr), indium-111 ("'1In), and rarely selenium-75 (75Se) and carbon-14 (14C). Using 11' In, 70% of the autologous platelets were distributed in the circulation, while the remaining were distributed to the spleen (20%) and liver (10%) (113) .
The fate of platelets after their re-entry in the circulation is variable. Either one or a combination of the following may occur: (i) a premature destruction by the reticuloendothelial system in cases of antiboby-mediated diseases (e.g. idiopathic thrombocytopenic purpura), (ii) consumption after interaction with the abnormal vasculature (e.g. systemic vasculitides or atherosclerotic vascular and heart valve diseases), and (iii) death of senescent platelets after sequestration in the liver and spleen (114, 115) .
Platelets have functional heterogeneity. This is indicated by radiolabeling studies with 51Cr.
These studies have also shown that the size of the platelets is unrelated to their age (i16-i19).
The most widely used radionuclide is 5'Cr in spite of the fact that it has a low labeling index, long half-life and low gamma photon yield (120) . 11"In (using oxine or tropolone as ligands) is superior in the precise determination of platelet kinetics because it has better visualization and quantification of platelet distribution than 51Cr (121) (122) (123) . Furthermore, 1"In-labeled platelets have better preservation of their function and are more closely related to in vivo turnover than platelets labeled with 51Cr. Both "1'In ligands (oxine and tropolone) were equally effective in the distribution studies (121) (122) (123) .
The most common application of the radionuclide methods is to describe platelet kinetics. However, a few studies assessed the correlation of platelet life span with the evolution of thrombotic events or several predisposing conditions like hypertension, diabetes mellitus, hyperlipidemia or previous thrombotic events.
Diabetic patients had a similar platelet life span when studied with 51Cr compared with the general population irrespective of the degree of vascular impairment (124) . However, in one third of the 31 studied patients with diabetes mellitus an increased consumption of platelets was observed. There was no correlation with the age, the clinical duration of diabetes mellitus, or extent of vascular disease present (124) .
Patients with familial hypercholesterolaemia (FH) may have premature atherosclerosis. In ten patients with FH and coexisting thrombotic complications, the mean platelet life span, estimated with "'In, was lower than that of normal subjects. The difference in the mean platelet life span was 25 hours (95% CI between 23-31 hours; p= 0.002). Similarly, mean platelet turnover, circulating platelet factor 4 (PF4), a factor released after platelet activation, and the mean circulating platelet aggregate ratio differed significantly from normal (125) . Patients with acute MI have a similar pattern with FH patients. Patients (n=26) with acute MI had a shorter life span and an increased platelet production rate compared with age-matched controls (126) .
Following aortic vascular surgery, mean platelet life span increases and a reduction in the production rate and blood platelet counts is observed (127) . However, early postoperatively, increased platelet production and count occurs (127) .
Platelet involvement in thrombotic coronary events was demonstrated by the determination of released PF-4 and P-TG in 91 patients with CHD (128) . Patients with the shortest platelet life span (5'Cr-labeled platelets) had higher concentrations of PF-4 and f-TG (128) . Some investigators do not support the concept that platelet turnover is enhanced in patients with angiographically proven diseased coronary arteries. Following 5'Cr-labeled autologous platelet infusion in 69 patients, platelet survival time was calculated by the decay of radioactivity and compared with 16 individuals with normal coronary arteries. There was no enhanced platelet turnover in patients with established coronary disease compared to those with normal coronary arteries. Also there was no correlation between platelet survival time and the extent of the arterial disease (64) .
Are these methods helpful in detecting platelet activation in vivo? There are serious reservations regarding the use of radiolabeling methods. Platelets are prepared after venupuncture and whole blood centrifugation. After several buffer washes and extracorporal incubation with the radionuclide and its ligand, platelets are returned to the patient (129, 130) . The test should be performed in a laboratory with experience in the management of radionuclide techniques. Operators also need to maintain sterility for the whole procedure. Therefore, these methods are expensive, time-consuming, and an extracorporal process is needed with a possible risk of infection. These disadvantages limit the use of such methods.
Aggregometry Procedures
The cornerstone for the assessment of platelet function is aggregometry, evaluated by turbidometric or impedance methods (65, 75) . Spontaneous platelet aggregation (SPA), or aggregation in response to several agonists such as ADP, collagen, thrombin, epinephrine, in PRP or whole blood can be assessed (50, 65) .
The turbidometric procedure is based on the detection of light transmission through a suspension of PRP before or after the addition of agonists, while platelets are kept in motion by a stirring system. The increase in light transmission is related to the extent of aggregation. This process is monitored photometrically and is plotted as a curve (131) . The addition of each agonist produces a different curve morphology that can be recognized.
The advantage of this method is that it is widely used and relatively simple to perform and interpret. However, we are not sure if these in vitro studies reflect platelet activation in vivo. Furthermore, centrifugation is required to obtain PRP. A platelet population of unknown function and number is lost after centrifugation; this may influence the results of the test (112, 132) .
Another method of determining platelet aggregation is whole blood aggregometry by the impedance method. Whole blood anticoagulated with citrate is continuously stirred. After the insertion of an electrode, impedance changes are recorded before or after the addition of agonists (50, 132) . The detection of platelet aggregation by this method is obtained in a millieu closer to that of platelets in vivo. Centrifugation is not required and white blood cells are present. The results obtained are broadly similar to those seen by turbidometric methods.
Aggregometry tests have been widely used to establish a causative relationship between activated platelets, CHD, and vascular risk factors. However, aggregometry procedures in PRP may provide a cheaper and quicker tool to estimate cardiovascular risk, while impedance changes in whole blood are slower, have poor reproducibility, and their cost is higher because of the use of the platinum electrodes that may need replacement. 11, 16, 19, 27, 28, 48, 50, 58, [78] [79] [80] [81] [82] 131, 132 Aggregometry procedures in subpopulations of the Caerphilly prospective study performed in PRP and whole blood failed to prove that increased platelet hyperactivity is significantly related to an increased risk of subsequent CHD (78) (79) (80) (81) (82) . However, there is evidence of such a link from some other studies (83) . Some investigators propose that SPA in PRP could predict the risk of subsequent events and death after MI (84) .
A negative predictive association was also paradoxically observed between platelet aggregation and stroke in the Caerphilly Collaborative Study (82) . Possible underlying mechanisms for this finding are not clear. A negative association between platelet aggregation and thrombotic events has also been described in patients with peripheral arterial disease (133) . An explanation proposed by these authors is that platelets were activated in vivo and therefore refractory to agonists added in vitro (133) . However, in the same study elevated ,-TG levels (presumably released by activated platelets) reflected in vivo platelet activation. An alternative explanation for the paradoxical findings would be the delay in the assessment of platelet aggregation (up to 90 minutes). This is a rather long period to assess platelet aggregation, especially if there is hyperactivity; during this delay SPA may have occurred. Similarly, the centrifugation step required to obtain PRP might have influenced platelet counts and theiractivity.
Determination of Platelet Contents Released in Serum
Substances stored in platelet oc-granules like PF-4 and 1-TG, can be detected by ELISA or radioimmunoassay methods and could serve as indices of platelet activation (65, 66) . However, major limitations include the rapid binding of PF-4 to endothelial cells (66) . Also, elevated circulating levels of f3-TG occur in patients with renal insufficiency because this platelet release product is metabolized and excreted by the kidney (66) . Heparin can also alter plasma levels of PF-4 because this anticoagulant facilitates the release of PF-4 bound to endothelial cells (66) . An additional limitation in the wide use of these substances as a measure of platelet activation is that any in vitro platelet activation during the preparation stages (e.g., centrifugation) may influence the results. Nevertheless, the simultaneous measurement of these two factors may allow better evaluation of platelet in vivo activation when aggregometry or flow cytometry are not accessible.
Another platelet granule content, P-selectin, could serve as measure of platelet activation. Its use in detecting platelet activation is discussed in the section dealing with adhesion molecules.
Platelet-Specific Eicosanoids
Activated platelets can synthesize the eicosanoid, TXA2 which has a very short half-life (30 seconds) and is spontaneously degraded to the more stable TXB2 Platelet activation can be indicated either by measuring TXB2 levels in serum, in plasma or after aggregation in vitro (89) . Furthermore, TXB2 metabolites can be measured in the urine (89) .
Agonist-induced platelet aggregation and subsequent TXA2 release has been used as a useful marker of platelet activity (89) . However, the detection of platelet activation by measuring TXA2 release, or related metabolites in the urine in patients taking cycloxygenase inhibitors (aspirin or other non-steroidal anti-inflammatory drugs), nifedipine, or nimodipine is limited because TXA2 release is inhibited by these compounds (134) . Increased alcohol ingestion also inhibits platelet TXA2 release (135) .
Other Release Reactions: Serotonin
Serotonin (5-hydroxytryptamine; 5-HT), a content of dense granules, is released in the serum after platelet activation (136) . 5 -HT released in plasma activates platelets and can induce vasoconstriction. Plasma 5-HT levels can be detected by radioimmunoassay methods (136) . Intraplatelet 5-HT levels range with age; younger patients have increased 5-HT levels compared with the elderly. Moreover, intraplatelet 5-HT levels are significantly decreased in patients with non-insulin dependent diabetes mellitus and peripheral arterial disease (136) . These findings probably indicate platelet activation in these diseases (136) . Furthermore, elevated 5-HT circulating levels are significantly related with postoperative stenosis in patients who had an infrainguinal graft (137) .
Moreover, naftidrofuryl, a drug used for the symptomatic treatment of peripheral arterial disease, inhibits platelet shape change and aggregation in healthy subjects and peripheral arterial disease patients by inhibiting 5-HT-induced platelet activation (109, 138, 139) .
The clinical significance of intraplatelet 5-HT in platelet activation and consequent MI was indicated in a case control study including patients with depression and MI. Patients receiving selective 5-HT re-uptake inhibitors (SSRIs), a group of drugs for the treatment of depression, causing 5-HT depletion in platelets, had an odds ratio (OR) of 0.35 for MI compared with patients not using an SSRI (140) .
Thus, the determination of 5-HT in plasma could serve as a measure of platelet activation. Limitations in the wide use of this test as an indicator of platelet activation include the variation of 5-HT levels with age and the possibility of artefactual platelet aggregation and 5-HT release during venepuncture and the preparation stage.
Histamine
A less well-investigated method reflecting platelet activation is the uptake of histamine by platelets (141) . Stirring increased histamine uptake by human platelets in vitro (141) . The addition of sub-aggregatory concentrations of conventional platelet agonists (e.g., epinephrine) also significantly increased platelet histamine uptake (141) . Thus, histamine uptake by platelets could serve as a useful index of platelet behavior in conditions where platelets are activated (e.g., peripheral arterial disease and diabetes mellitus) (141) . Following platelet activation 5-HT is released from platelets (136, 137) , whereas histamine uptake is increased (141) . Therefore, the intraplatelet content of these bioamines may follow an opposite pattern.
Adhesion Molecules
Activated platelets interact with endothelial cells through adhesion molecules belonging to the family of integrins (GP la/IIa, GPIc/IIa, GPIIb/IIIa, GPIb/V/IX, GP I/V), selectins (P-selectin), and immunoglobulin-like adhesion molecules (ICAM-1, PECAM-1) (56). P-selectin is found in both platelets ox-granules and endothelial cells. P-selectin is not expressed on normal resting platelets. Platelet activation leads to a rapid release and surface expression of P-selectin. Secreted by platelets, P-selectin either remains attached to the membrane or is released in the plasma. Surface and soluble P-selectin have been well recognized as markers of platelet activation and their levels are increased in several thrombotic disorders (54, (67) (68) (69) (70) (71) (72) (73) (74) .
Increased plasma soluble P-selectin levels could reflect in vivo platelet activity, in healthy individuals at high risk of vascular events. There are also sufficient data indicating that patients with stable CHD have elevated soluble P-selectin levels (72) . Moreover, apparently healthy women in whom cardiovascular events developed subsequently had significantly elevated soluble P-selectin levels (p= 0.01) compared with those who did not (73) . This increase is related to platelet activation and does not originate from endothelial cells (72, 73) . Additionally, soluble Pselectin can be considered as a reasonable marker for thrombotic events in patients with nephrotic syndrome (74) . Soluble P-selectin determination can be performed in plasma (stored at -80°C) by an ELISA method. This assay requires moderately expensive equipment (70) (71) (72) (73) (74) . Various anticoagulants used for plasma collection (heparin, EDTA, or sodium citrate in different concentrations) influence soluble P-selectin levels. Therefore, there is a need to establish optimal anticoagulation to obtain better diagnostic validation (71) .
Flow Cytometric Investigations
A major advance in the assessment of in vivo platelet activation was the introduction of flow cytometry (75, (142) (143) (144) (145) .
Flow cytometry analysis in combination with fluorochrome-labeled monoclonal antibodies makes possible the detection of specific alterations related with activation on the surface of platelets. Flow cytometry analyzes individual cells in continuous flow using a laser beam. The scattered light and the intensity of the fluorescence are recorded by specific photodiodes. This test can provide information about platelet size, granularity and surface expression of molecules (e.g., P-selectin) or fluorescence-labeled surface receptors (fibrinogen). The functional state and conformational changes of the surface receptors GP IIb/IIIa, GP Ib/V/IX, the activated fibrinogen receptor or bound fibrinogen on the platelet surface can also recognized by selected monoclonal antibodies (75, 90, 91, 142, 143) .
Platelet degranulation markers are also available. Thus, platelet surface P-selectin and GP-53, indicating degranulation of oc-granules and lysosomes respectively, can be detected (57, 75, 90, 142, 143) .
Platelet-leucocyte aggregates and small membrane vesicles (the microparticles) extend the technology for the diagnosis of platelet activation by flow cytometry methods (55, 91, 92, 145) . These two early markers of platelet activation indicate a significant prothrombotic activity (145) .
The evaluation of platelet function by flow cytometry showed increased platelet activation in patients at high-risk for cardiovascular events, with stable and unstable angina, acute MI, and after coronary angioplasty and stent implantation (146) . The monitoring of intensive antiplatelet treatment with intravenous GP Ilb/IIla receptor antagonists after interventional procedures is another application of this technique (146) .
Determination of platelet activation by flow cytometry must be carried out in citrated blood and this process requires the addition of buffers, paraformaldehyde (for platelet fixation) and specific fluorochromes (144, 145) .
Although flow cytometry can detect early platelet activation, the need for specialized laboratories with high cost equipment and reagents, and the need for experienced operators are serious limitations for the wide application of this method (55, 75, (90) (91) (92) 144, 145) .
Platelet Count and Bleeding Time
Electronic counters, available in hematologic laboratories routinely provide platelet counts. There is evidence that the platelet count can predict the risk of death and cardiovascular disease (83) . For example, in apparently healthy people an elevated platelet number is related to increased mortality after a first MI (83) . Furthermore, after MI lower mean platelet counts are related to the infarct size (87, 88) . This latter change may reflect platelet consumption during MI.
Another simple test for estimating platelet function is the bleeding time (BT). The BT rep-resents the time between vascular injury and platelet thrombus formation. The BT estimates platelet number and function, adhesion, aggregation, and the interactions between platelet and vessel wall. Factors affecting BT are fibrinogen, other coagulation proteins, antiplatelet treatment, uremia, hepatic dysfunction, and vessel wall disorders. Congenital platelet disorders (e.g., Glanzmann disease, Bernard-Soulier syndrome) can also influence BT.
The BT can be determined after making a standardized wound with a blade. The time until cessation of bleeding is measured. Normal values range between 5 and 10 minutes. Serious limitations of this test are the discrepancy between different operators skin temperature, as well as the depth and the length of the wound. Thus, this test cannot provide a precise estimation of platelet function. There may also be a residual scar and in our experience some patients refuse repeated testing.
Newer Methods of Estimating Platelet Function
PFA-100 is a platelet function analyzer that uses citrated whole blood. In brief, this instrument monitors the time needed to stop the flow of blood in the presence of agonists (e.g., collagen, epinephrine, or ADP) through a small aperture. This is the closure time and it reflects platelet adhesion and aggregation. This assay is automated, quick and easy to use (147) (148) (149) (150) (151) .
However, limitations are the need for standardization and validation using other more established methods. The cost of each test performance is also high because the cartridge must be replaced. The possibility of ex vivo platelet activation is significant during venupuncture or at the stage of preparation.
Thromboelastography
Thromboelastography (TEG) is a useful and rapid measure of coagulation (152) (153) (154) . However, TEG is not a comprehensive or sensitive reflection of impaired platelet function or count (152) (153) (154) . Therefore, TEG should be supplemented by other methods of estimating platelet function whenever possible (152) (153) (154) .
Other Less Well-Established Tests Used to Detect Platelet Activation
The enzyme y-glutamyl transpeptidase (y-GT) replenishes intracellular glutathione and possibly controls apoptosis and proliferation in atheromatous plaques (155, 156) . Through this mechanism y-GT is possibly associated with in-creased cardiovascular risk. It has been proposed that some of the circulating y-GT may originate from atheromatous plaques (155, 156) .
There is also evidence that patients with increased platelet counts have a marginally, but significantly, higher serum y-GT activity in the absence of liver disease (157) . Therefore, platelets may contribute to increased serum y-GT activity (157) . Moreover, increased platelet consumption and destruction at the site of atheromatous plaques may contribute to an elevation in serum y-GT activity (158) . This easily measurable enzyme, in serum, may become a useful marker of vascular disease and platelet activity. Such a concept needs further confirmation because any platelet-related change in y-GT activity would be small. However, the value of measuring y-GT activity could be enhanced by restricting it to the y-GT isoenzyme present in human platelets.
Plasma Factors Influencing Platelet Activation
Fibrinogen has been recognized as an emerging risk factor for cardiovascular risk. Beyond its action as a circulating coagulation factor and major determinant of blood viscosity, fibrinogen serves as a cofactor in platelet aggregation (137, 159) .
Furthermore, several studies propose that albumin acts as an antioxidant. Moreover, decreased plasma albumin levels are related with platelet activation and thrombogenesis (160, 161) .
Dyslipidaemia may also be associated with platelet activation. This is reversed when lipidlowering drugs are used (39, 46, 137) .
Several bioactive compounds (e.g. 5-HT, angiotensin II, endothelin-1) in the circulation may also influence platelet activity (14, 108, 109, 136, 137) . However, the value (in terms of reducing platelet activation) of altering the levels of these plasma factors has not been established.
CONCLUSIONS
The rationale for using a methodologically simple test would be to detect platelet activation in healthy subjects and thus, identify those at high risk for CHD. In those with established vascular disease antiplatelet therapy could be optimized to provide maximum clinical benefit. The administration of appropriate pre-emptive antiplatelet therapy with aspirin or one of the newer antiplatelet drugs should then reduce the incidence of cardiovascular events (31-37).
Measuring SPA, or aggregation in response to agonists (e.g. ADP, thrombin, collagen and epinephrine), in whole blood or in PRP seems to be relatively easy and inexpensive, but time consuming. A fresh blood sample is also needed. However, there is no convincing evidence that these methods predict the risk of vascular events (71) (72) (73) (74) (75) (76) (77) .
A simple diagnostic test is determining the MPV. However, to our knowledge there is no primary prevention study indicating its efficacy in predicting CHD. Nevertheless, secondary prevention studies indicate a substantial risk of recurrent MI among patients with a history of unstable angina and MI and a significantly increased MPV. Some controversies concerning the predictive value of MPV, is the absence of welldefined limits to differentiate between activated and non-activated platelets. There is also no evidence that antiplatelet therapy reverses an increased MPV. This omission is indeed surprising and it may indicate a negative predictive value for the MPV (4, 44, 45) .
Newer methods estimating CHD risk using flow cytometry are expensive and not available in routine laboratories. Furthermore, the evidence so far is mainly limited to the short-term assessment of patients with established vascular disease (64, 68, 69, 81) .
A promising method could be the determination of plasma soluble P-selectin levels by an ELISA method. This can be made available in most laboratories and samples can be stored (54) . However, all trials using this method recruited relatively small numbers of patients with already established CHD (46, 47, 58, 60, (62) (63) (64) (65) (66) (67) (68) .
We conclude that, currently, the more widely established method for estimating platelet activation is aggregometry in PRP (or in whole blood). However, this method although widely used, has limited evidence showing that it predicts the risk of vascular events.
Two promising methods, for widespread use, are the MPV and plasma soluble P-selectin determination. These methods do not require expensive or special equipment but there is insufficient evidence showing that they consistently predict the risk of cardiovascular events especially in the healthy population. These methods need to be evaluated in primary and secondary prevention studies.
In conclusion, a test effective in predicting CHD could be used to monitor the efficacy of antiplatelet treatment. Hence, we would be able to optimize therapy and reduce side effects. Cost could also be reduced since simple and inexpensive antiplatelet drugs may be shown to be as safe and effective in certain patients as more expensive drugs or combination treatment.
